Inscripta, a leading gene-editing technology company, announced that it has closed a $55.5 million Series C funding round led by Mérieux Développement and Paladin Capital Group.
Additional participants include all existing Inscripta investors: Venrock, Foresite, MLS Capital, and NanoDimension. The new funding comes on the heels of the company’s release of its first CRISPR enzyme (MAD7), and will accelerate Inscripta’s development and commercialization of gene-editing tools, including instruments, reagents, and software, and grow the company’s expert team.
“Gene editing is one of the most exciting scientific advancements of this young century, but to realize its full potential, researchers need to have better, more scalable tools to forward engineer proteins, pathways and genomes,” said Kevin Ness, CEO of Inscripta. “The past 20 years of genomic advancements have been in the field of genome reading, but we believe that future advancements in biology will be in the applications of genome writing.”
Inscripta will use the funding to expand its research capabilities and strengthen its internal team of high-performing research experts. The company has open positions that offer growth opportunities for scientists and engineers in the fields of microfluidics, genomics, cell biology, synthetic biology, and computational biology at locations in both Boulder, Colo. and the Bay Area. In addition, the company is significantly expanding its commercialization efforts.
At the close of last year, Inscripta introduced its MAD7 enzyme, which is fully available for commercial and academic researchers with no up-front licensing fees or “reach-through royalties” on products made using the technology. This unique approach was the first step in the company’s path to re-shape forward genome engineering and make it more accessible for the research community.
Inscripta is a gene-editing technology company that puts researchers in control by making it easy for them to get all they need for cutting-edge, forward cell-engineering. These tools include a family of CRISPR enzymes (called MADzymes), custom nucleases for researchers and commercial partners, and a full suite of gene-editing tools (instruments, reagents, and software) that will significantly increase the speed and efficiency of multiplexed, precision gene editing.